Every material Form 8-K BIOCRYST PHARMACEUTICALS INC has filed with the SEC since June 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
BioCryst reported third quarter 2026 total revenue of $180.3 million, up 13% from a year earlier, and GAAP net income of $37.9 million, compared with $12.9 million in the same quarter of 2025. The company raised its full year 2026 total revenue outlook to $715 million to $730 million and lowered its non-GAAP operating expense outlook to $415 million to $425 million, while keeping its ORLADEYO revenue outlook at $625 million to $645 million. The filing says part of the revenue growth reflects an initial inventory build by its new specialty pharmacy, CareMed.
Q3 2026 total revenue was $180.3 million, up from $159.4 million in Q3 2025; GAAP net income was $37.9 million, or $0.14 per diluted share, versus $12.9 million.
Full year 2026 total revenue guidance was raised to $715 million to $730 million from $690 million to $715 million, driven mainly by navenibart rights licensing and higher RAPIVAB orders.
ORLADEYO revenue guidance was unchanged at $625 million to $645 million; non-GAAP operating expense guidance was lowered to $415 million to $425 million from $420 million to $440 million.
The Birmingham site closure is expected to cost about $10 million in cash and produce annualized savings of $30 million to $35 million once fully realized.
BioCryst reported second quarter 2026 total revenue of $218.3 million, up 34% from a year earlier, and GAAP net income of $78.4 million, or $0.30 per diluted share, compared with $5.1 million, or $0.02 per diluted share, a year earlier. The company raised its full year 2026 total revenue outlook to $690 million to $715 million and lowered its non-GAAP operating expense outlook to $420 million to $440 million, while keeping its ORLADEYO revenue outlook at $625 million to $645 million.
Q2 2026 total revenue $218.3 million (up 34% year over year); ORLADEYO revenue $158.2 million (up 1%)
GAAP operating profit $98.5 million in Q2 2026 versus $29.8 million in Q2 2025; non-GAAP operating profit $113.2 million
Full year 2026 total revenue outlook raised to $690 million to $715 million from $635 million to $660 million
Non-GAAP operating expense outlook lowered to $420 million to $440 million from $450 million to $470 million; six-month GAAP net loss of $643.4 million includes a $697.8 million acquired in-process R&D charge tied to the Astria acquisition
BioCryst said its board approved on June 25, 2026 a plan to discontinue internal discovery programs and close its Birmingham, Alabama facility, with the work substantially complete by the end of 2026. The company cannot yet estimate the total cost of the plan and will file an amendment once it does, while lowering its 2026 non-GAAP operating expense guidance and reaffirming revenue guidance.
Board approved the plan on June 25, 2026; implementation expected to be substantially complete by the end of 2026.
Total costs of the plan are not yet estimated; expected costs include contract, lease and employee termination and severance.
2026 non-GAAP operating expense guidance lowered to $420 million to $440 million from $450 million to $470 million.
Total 2026 revenue guidance of $635 million to $660 million is reaffirmed; ORLADEYO oral pellets expected to be available in early August 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BIOCRYST PHARMACEUTICALS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →